Saturday 17 October 2026
Export LFCR’s income statement to Excel — free account
Lifecore Biomedical, Inc.
LFCR Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, revenue fell 6.25%, EPS fell 216.7%, free cash flow fell 117.0% and total debt rose 15.3%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
6.38
0.06
−0.93%
Follow LFCR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | — | 0.00 | 0.00 |
P/S ratio |
2.21 | — | 1.14 | 1.65 | |
P/FCF ratio |
20.90 | — | 10.32 | 0.00 | |
P/Operating CF |
(57.52) | — | 29.66 | (90.12) | |
P/B ratio |
0.00 | — | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | — | 0.00 | 0.00 | |
EV/Sales |
3.35 | — | 2.19 | 3.06 | |
EV/EBITDA |
0.00 | — | 0.00 | 0.00 | |
EV/Operating CF |
28.96 | — | 19.39 | (713.10) | |
EV/FCF |
31.71 | — | 19.79 | (72.23) | |
Quick Ratio |
1.46 | 1.85 | 1.96 | 2.20 | |
Current Ratio |
2.80 | 3.49 | 3.79 | 3.87 | |
Net Debt/EBITDA |
(27.90) | 0.00 | (53.76) | 33.01 | |
Debt/Assets |
68.24% | 72.29% | 65.53% | 80.62% | |
Debt/Equity |
4.36 | 4.93 | 7.11 | 11.50 | |
Asset Turnover |
0.51 | 0.00 | 0.52 | 0.51 | |
Operating CF/Net income |
0.44 | — | (0.29) | 0.31 | |
Capex/Depreciation |
0.59 | — | (0.48) | (0.20) | |
Interest Coverage |
(0.48) | — | (0.64) | 0.33 | |
Research and Development Expense of Revenue |
6.31% | — | 5.25% | 4.50% | |
Selling, General and Administrative Expense of Revenue |
28.59% | — | 34.14% | 23.33% | |
Intangible Assets out of Total Assets |
0.08 | 0.06 | 0.06 | 0.06 | |
Share Based Compensation of Revenue |
(6.35%) | — | 7.32% | 6.10% | |
Graham Net Nets |
(0.42) | — | (0.91) | (0.66) | |
Graham Number |
2.36 | — | 3.79 | 4.45 | |
Earnings Yield |
(11.96%) | — | (22.58%) | (18.48%) | |
Free Cash Flow Yield |
4.78% | — | 9.69% | (2.57%) | |
Revenue per Share |
0.83 | — | 0.62 | 0.91 | |
Operating CF per Share |
(0.13) | — | 0.13 | (0.06) | |
Capex per Share |
(0.03) | — | (0.03) | (0.01) | |
Free Cash Flow per Share |
(0.16) | — | 0.10 | (0.07) | |
Cash per Share |
0.50 | 0.00 | 0.55 | 0.46 | |
Shareholders Equity per Share |
0.98 | 0.00 | 0.55 | 0.43 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.98 | 0.00 | 0.55 | 0.43 | |
Free Cash Flow |
(5.97) | — | 3.58 | (2.70) | |
Working Capital |
53.97 | 58.72 | 57.14 | 62.05 | |
Capital Expenditures |
(1.18) | — | (1.12) | (0.51) | |
Net Current Asset Value |
(114.49) | (115.82) | (127.08) | (129.72) | |
EV/EBIT |
92.41 | — | 0.00 | 0.00 | |
Capex to Sales |
0.04 | — | 0.05 | 0.02 | |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
27.53 | 26.83 | 24.06 | 27.60 | |
Average Payables |
12.54 | 6.81 | 7.62 | 8.82 | |
Average Inventory |
36.51 | 31.84 | 30.22 | 29.64 | |
Average Assets |
245.30 | 234.94 | 232.42 | 232.35 | |
Average Common Equity |
2.46 | (5.99) | (13.55) | (22.32) |
Columns are period end dates